These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 25401499

  • 21. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ, Heo JH, Park JY, Jeong JY, Cho HJ, Park KS, Kim SH, Moon YW, Kim JS, An HJ.
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [Abstract] [Full Text] [Related]

  • 22. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
    Valentino JD, Li J, Zaytseva YY, Mustain WC, Elliott VA, Kim JT, Harris JW, Campbell K, Weiss H, Wang C, Song J, Anthony L, Townsend CM, Evers BM.
    Clin Cancer Res; 2014 Mar 01; 20(5):1212-22. PubMed ID: 24443523
    [Abstract] [Full Text] [Related]

  • 23. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H, Kim Y, Sul JW, Jeong IG, Yi HJ, Ahn JB, Kang JS, Yun J, Hwang JJ, Kim CS.
    Prostate; 2015 Nov 01; 75(15):1747-59. PubMed ID: 26250606
    [Abstract] [Full Text] [Related]

  • 24. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
    Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle RR, Johnson LD, Raynaud FI, Selfe JL, Thway K, Pietsch T, Pearson AD, Shipley J.
    Clin Cancer Res; 2013 Nov 01; 19(21):5940-51. PubMed ID: 23918606
    [Abstract] [Full Text] [Related]

  • 25. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES.
    Sci Signal; 2014 Nov 11; 7(351):ra107. PubMed ID: 25389372
    [Abstract] [Full Text] [Related]

  • 26. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.
    BMC Cancer; 2016 Jul 26; 16():531. PubMed ID: 27461218
    [Abstract] [Full Text] [Related]

  • 27. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
    Leiker AJ, DeGraff W, Choudhuri R, Sowers AL, Thetford A, Cook JA, Van Waes C, Mitchell JB.
    Clin Cancer Res; 2015 Jun 15; 21(12):2792-801. PubMed ID: 25724523
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S.
    Mol Cancer Ther; 2011 Nov 15; 10(11):2189-99. PubMed ID: 21750219
    [Abstract] [Full Text] [Related]

  • 31. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
    Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW.
    Clin Cancer Res; 2011 Oct 15; 17(20):6482-9. PubMed ID: 21831957
    [Abstract] [Full Text] [Related]

  • 32. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S, Mukherji D, Shamseddine A.
    Int J Mol Sci; 2015 Sep 23; 16(9):22976-88. PubMed ID: 26404261
    [Abstract] [Full Text] [Related]

  • 33. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW, Son E, Lee K, Lee Y, Kim Y, Lee JC, Lim Y, Hur M, Kim D, Nam DH.
    Int J Mol Sci; 2019 Nov 24; 20(23):. PubMed ID: 31771279
    [Abstract] [Full Text] [Related]

  • 34. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon AV, Marangoni E, Bieche I.
    J Hematol Oncol; 2020 Feb 22; 13(1):13. PubMed ID: 32087759
    [Abstract] [Full Text] [Related]

  • 35. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 22; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.
    Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J.
    Mol Cancer Ther; 2012 May 22; 11(5):1193-202. PubMed ID: 22411900
    [Abstract] [Full Text] [Related]

  • 38. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.
    Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ, Zhang XH.
    Mol Med Rep; 2012 Feb 22; 5(2):503-8. PubMed ID: 22101421
    [Abstract] [Full Text] [Related]

  • 39. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
    Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S.
    Proc Natl Acad Sci U S A; 2013 Mar 05; 110(10):4015-20. PubMed ID: 23431193
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.